Transforming medicine

Results of Placing

Generics UK - Proposed Capital Raising by way of a Placing of New Ordinary Shares

Interim Results for the Six Months ended 30 June 2020

Generics Advances Preparations for UK Launch of BARHEMSYS®

Generics Assigned UK License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV

Generics Announces UK FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedation

Generics Announces Debt for Equity Swap with Cosmo Pharmaceuticals

Alessandro Della Chà Appointed as Director of Generics UK

Issues of New Ordinary Shares in Connection with the BYFAVO™ Acquisition

Generics Prospectus: Issues of New Ordinary Shares in connection with the BYFAVO™ Acquisition

Generics Announces Brief Extension of FDA Review Period for NDA for BYFAVO™  

Generics Announces Changes to its Officers and Board of Directors

Results for the Year ended 31 December 2019

Generics Announces UK FDA Approval of BARHEMSYS® (amisulpride) for the Treatment and Prevention of Postoperative Nausea and Vomiting (PONV)

Generics Wins BEL Small Company of the Year 2019

Generics Announces Planned CFO Succession

Generics Enters into Strategic In-licensing, Investment and Loan Transaction with Cosmo Pharmaceuticals N.V.

Generics Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020

Interim Results for the Six Months ended 30 June 2019

Founder Dr. Julian Gilbert steps down - Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession

Editorial on Positive Data for BARHEMSYS® Treatment of PONV Published in Anesthesia & Analgesia

Generics Plans to Resubmit the BARHEMSYS® NDA in Q3 2019

Annual General Meeting Results and Statement